Wetzel Investment Advisors »

Chemomab Therapeutics shares owned by Wetzel Investment Advisors

Quarter-by-quarter ownership of Chemomab Therapeutics (CMMB) shares owned by Wetzel Investment Advisors from 13F filings

Historical chart of Wetzel Investment Advisors investment in Chemomab Therapeutics

23:59:59.999Dec 30, 202423:59:59.999500:00:00Dec 31, 202400:00:00.000500:00:00.00118.099k18.0995k18.1k18.1005k18.101k9.999k9.9995k10k10.0005k10.001k
Value ($)Share countHistorical CMMB position of Wetzel Investment Advisors Source: stockzoa.comValue ($)Share count

Tip: Access up to 7 years of quarterly data

All positions including Chemomab Therapeutics held by Wetzel Investment Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Chemomab Therapeutics by Wetzel Investment Advisors

Quarter filed Position value Share count Share price at filing
2024-12-31 $18k 10k 1.81

More positions owned by Wetzel Investment Advisors

Ishares Tr Rus 1000 Grw Etf (IWF)
Vanguard Star Fds Vg Tl Intl Stk F (VXUS)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
JPMorgan Chase & Co. (JPM)
Eli Lilly & Co. (LLY)
Invesco Exchange Traded Fd T S&p500 Quality (SPHQ)
Vanguard Index Fds Value Etf (VTV)
Spdr Ser Tr Portfolio Intrmd (SPIB)
Vanguard Index Fds Extend Mkt Etf (VXF)
Ishares Core Msci Emkt (IEMG)
Ishares Tr Core S&p Scp Etf (IJR)
First Tr Morningstar Divid L SHS (FDL)
Innovator Etfs Trust Quity Managd Flr (SFLR)
Vanguard Intl Equity Index F Tt Wrld St Etf (VT)
Ishares Tr Conv Bd Etf (ICVT)

View all positions for Wetzel Investment Advisors

Top funds holding Chemomab Therapeutics

OrbiMed Advisors
Sphera Funds Management
Yelin Lapidot Holdings Management
Ikarian Capital
Morgan Stanley
Kestra Private Wealth Services
Boothbay Fund Management
XTX Topco
Rhumbline Advisers
Virtu Financial
Wetzel Investment Advisors
Bnp Paribas Arbitrage, Snc
GAMMA Investing
Moser Wealth Advisors
UBS Group

View all funds holding Chemomab Therapeutics